Major depressive disorder (MDD or depression) is a debilitating neuropsychiatric syndrome with genetic, epigenetic, and environmental contributions. Depression is one of the largest contributors to chronic disease burden; it affects more than one in six individuals in the United States. A wide array of cellular and molecular modifications distributed across a variety of neuronal processes and circuits underlie the pathophysiology of depression—no established mechanism can explain all aspects of the disease. MDD suffers from a vast treatment gap worldwide, and large numbers of individuals who require treatment do not receive adequate care. This mini-review focuses on dysregulation of brain dopamine (DA) systems in the pathophysiology of MDD and describing new cellular targets for potential medication development focused on DA-modulated micro-circuits. We also explore how neurodevelopmental factors may modify risk for later emergence of MDD, possibly through dopaminergic substrates in the brain.
American Psychiatric Association DSMTF. In: American Psychiatric A, American Psychiatric Association DSMTF (eds) Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA: American Psychiatric Association, 2013
2.
KesslerRCBerglundPDemlerOJinRKoretzDMerikangasKRRushAJWaltersEEWangPS.The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA2003;
289:3095–105
3.
MoussaviSChatterjiSVerdesETandonAPatelVUstunB.Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet2007;
370:851–8
4.
BelujonPGraceAA.Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol2017;
20:1036–46
5.
HeshmatiMRussoSJ.Anhedonia and the brain reward circuitry in depression. Curr Behav Neurosci Rep2015;
2:146–53
6.
LiuBLiuJWangMZhangYLiL.From serotonin to neuroplasticity: evolvement of theories for major depressive disorder. Front Cell Neurosci2017;
11:305
7.
KupferDJFrankEPhillipsML.Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet2012;
379:1045–55
8.
AkilHGordonJHenRJavitchJMaybergHMcEwenBMeaneyMJNestlerEJ.Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev2018;
84:272–88
9.
WrayNRRipkeSMattheisenMTrzaskowskiMByrneEMAbdellaouiAAdamsMJAgerboEAirTMAndlauerTMFBacanuSABækvad-HansenMBeekmanAFTBigdeliTBBinderEBBlackwoodDRHBryoisJButtenschønHNBybjerg-GrauholmJCaiNCastelaoEChristensenJHClarkeTKColemanJIRColodro-CondeLCouvy-DuchesneBCraddockNCrawfordGECrowleyCADashtiHSDaviesGDearyIJDegenhardtFDerksEMDirekNDolanCVDunnECEleyTCErikssonNEscott-PriceVKiadehFHFFinucaneHKForstnerAJFrankJGasparHAGillMGiusti-RodríguezPGoesFSGordonSDGroveJHallLSHannonEHansenCSHansenTFHermsSHickieIBHoffmannPHomuthGHornCHottengaJJHougaardDMHuMHydeCLIsingMJansenRJinFJorgensonEKnowlesJAKohaneISKraftJKretzschmarWWKroghJKutalikZLaneJMLiYLiYLindPALiuXLuLMacIntyreDJMacKinnonDFMaierRMMaierWMarchiniJMbarekHMcGrathPMcGuffinPMedlandSEMehtaDMiddeldorpCMMihailovEMilaneschiYMilaniLMillJMondimoreFMMontgomeryGWMostafaviSMullinsNNauckMNgBNivardMGNyholtDRO'ReillyPFOskarssonHOwenMJPainterJNPedersenCBPedersenMGPetersonREPetterssonEPeyrotWJPistisGPosthumaDPurcellSMQuirozJAQvistPRiceJPRileyBPRiveraMSaeed MirzaSSaxenaRSchoeversRSchulteECShenLShiJShynSISigurdssonESinnamonGBCSmitJHSmithDJStefanssonHSteinbergSStockmeierCAStreitFStrohmaierJTanseyKETeismannHTeumerAThompsonWThomsonPAThorgeirssonTETianCTraylorMTreutleinJTrubetskoyVUitterlindenAGUmbrichtDVan der AuweraSvan HemertAMViktorinAVisscherPMWangYWebbBTWeinsheimerSMWellmannJWillemsenGWittSHWuYXiHSYangJZhangFAroltVBauneBTBergerKBoomsmaDICichonSDannlowskiUde GeusECJDePauloJRDomeniciEDomschkeKEskoTGrabeHJHamiltonSPHaywardCHeathACHindsDAKendlerKSKloiberSLewisGLiQSLucaeSMaddenPFAMagnussonPKMartinNGMcIntoshAMMetspaluAMorsOMortensenPBMüller-MyhsokBNordentoftMNöthenMMO'DonovanMCPacigaSAPedersenNLPenninxBPerlisRHPorteousDJPotashJBPreisigMRietschelMSchaeferCSchulzeTGSmollerJWStefanssonKTiemeierHUherRVölzkeHWeissmanMMWergeTWinslowARLewisCMLevinsonDFBreenGBørglumADSullivanPF.Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet2018;
50:668–81
10.
UchidaSYamagataHSekiTWatanabeY.Epigenetic mechanisms of major depression: targeting neuronal plasticity. Psychiatry Clin Neurosci2018;
72:212–27
11.
HoffmannASportelliVZillerMSpenglerD.Epigenomics of major depressive disorders and schizophrenia: early life decides. Int J Mol Sci 2017;
18:1711.
12.
TargumSDNemeroffCB.The effect of early life stress on adult psychiatric disorders. Innov Clin Neurosci2019;
16:35–7
13.
DumanRSSanacoraGKrystalJH.Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron2019;
102:75–90
14.
IsellaVIurlaroSPioltiRFerrareseCFrattolaLAppollonioIMelziPGrimaldiM.Physical anhedonia in Parkinson's disease. J Neurol Neurosurg Psychiatry2003;
74:1308–11
15.
StraussGPGoldJM.A new perspective on anhedonia in schizophrenia. Am J Psychiatry2012;
169:364–73
16.
PizzagalliDA.Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol2014;
10:393–423
17.
TreadwayMTZaldDH.Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev2011;
35:537–55
18.
KleinDF.Endogenomorphic depression. A conceptual and terminological revision. Arch Gen Psychiatry1974;
31:447–54
19.
NuttDJ.Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry2008;
69Suppl E1:4–7
20.
FrederickALYanoHTrifilieffPVishwasraoHDBiezonskiDMészárosJUrizarESibleyDRKellendonkCSonntagKCGrahamDLColbranRJStanwoodGDJavitchJA.Evidence against dopamine D1/D2 receptor heteromers. Mol Psychiatry2015;
20:1373–85
21.
FlorescoSBTseMT.Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci2007;
27:2045–57
22.
PisaniABonsiPCentonzeDCalabresiPBernardiG.Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci2000;
20:Rc69
23.
StefaniADe MurtasMPisaniAStrattaFBonciAMercuriNBCalabresiP.Electrophysiology of dopamine D-1 receptors in the basal ganglia: old facts and new perspectives. Prog Neuropsychopharmacol Biol Psychiatry1995;
19:779–93
24.
KebabianJW.Multiple classes of dopamine receptors in mammalian central nervous system: the involvement of dopamine-sensitive adenylyl cyclase. Life Sci1978;
23:479–83
25.
SidhuA.Coupling of D1 and D5 dopamine receptors to multiple G proteins: implications for understanding the diversity in receptor-G protein coupling. Mol Neurobiol1998;
16:125–34
26.
SavastaMDuboisAScattonB.Autoradiographic localization of D1 dopamine receptors in the rat brain with [3H]SCH 23390. Brain Res1986;
375:291–301
27.
WamsleyJKGehlertDRFillouxFMDawsonTM.Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain. J Chem Neuroanat1989;
2:119–37
28.
BaikJH.Dopamine signaling in reward-related behaviors. Front Neural Circuits2013;
7:152
29.
YokoyamaNKunoTFuruyamaSWangJH.Immunological approach to identify calmodulin-stimulated phosphatase isozymes from bovine brain. Mol Cell Biochem1994;
132:101–8
30.
StanwoodGDArtymyshynRPKungMPKungHFLuckiIMcGonigleP.Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [(125)I]7-OH-PIPAT: evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther2000;
295:1223–31
31.
LiuLvan GroenTKadishITollefsbolTO.DNA methylation impacts on learning and memory in aging. Neurobiol Aging2009;
30:549–60
HaberSN.The place of dopamine in the cortico-basal ganglia circuit. Neuroscience2014;
282:248–57
35.
KapurSMannJJ.Role of the dopaminergic system in depression. Biol Psychiatry1992;
32:1–17
36.
FrancisTCLoboMK.Emerging role for nucleus accumbens medium spiny neuron subtypes in depression. Biol Psychiatry2017;
81:645–53
37.
NestlerEJCarlezonWAJr.The mesolimbic dopamine reward circuit in depression. Biol Psychiatry2006;
59:1151–9
38.
GraceAA.Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci2016;
17:524–32
39.
DeutchAYRothRH.The determinants of stress-induced activation of the prefrontal cortical dopamine system. Prog Brain Res1990;
85:367–402; discussion
40.
HorgerBARothRH.The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol1996;
10:395–418
41.
MoghaddamBJacksonM.Effect of stress on prefrontal cortex function. Neurotox Res2004;
6:73–8
42.
FinlayJMZigmondMJ.The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res1997;
22:1387–94
43.
AbercrombieEDKeefeKADiFrischiaDSZigmondMJ.Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem1989;
52:1655–8
44.
PezzeMAFeldonJ.Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol2004;
74:301–20
45.
CervoLSamaninR.Repeated treatment with imipramine and amitriptyline reduced the immobility of rats in the swimming test by enhancing dopamine mechanisms in the nucleus accumbens. J Pharm Pharmacol1988;
40:155–6
46.
ChenP.Optimized treatment strategy for depressive disorder. Adv Exp Med Biol2019;
1180:201–17
47.
KeksNAHopeJCastleD.Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?Australas Psychiatry2016;
24:289–91
48.
FornaroMFuscoAAnastasiaACattaneoCIDe BerardisD.Brexpiprazole for treatment-resistant major depressive disorder. Expert Opin Pharmacother2019;
20:1925–33
49.
MalletJGorwoodPLe StratYDubertretC.Major depressive disorder (MDD) and schizophrenia- addressing unmet needs with partial agonists at the D2 receptor: a review. Int J Neuropsychopharmacol2019;
22:651–64
50.
PlanchezBSurgetABelzungC.Animal models of major depression: drawbacks and challenges. J Neural Transm2019;
126:1383–408
51.
GururajanAReifACryanJFSlatteryDA.The future of rodent models in depression research. Nat Rev Neurosci2019;
20:686–701
52.
WangQTimberlakeMA 2ndPrallKDwivediY.The recent progress in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry2017;
77:99–109
53.
HershenbergRSatterthwaiteTDDaldalAKatchmarNMooreTMKableJWWolfDH.Diminished effort on a progressive ratio task in both unipolar and bipolar depression. J Affect Disord2016;
196:97–100
54.
Der-AvakianAD'SouzaMSPizzagalliDAMarkouA.Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research. Transl Psychiatry2013;
3:e297
55.
KaiserRHTreadwayMTWootenDWKumarPGoerFMurrayLBeltzerMPechtelPWhittonACohenALAlpertNMEl FakhriGNormandinMDPizzagalliDA.Frontostriatal and dopamine markers of individual differences in reinforcement learning: a multi-modal investigation. Cereb Cortex2018;
28:4281–90
56.
DavisGLStewartAStanwoodGDGowrishankarRHahnMKBlakelyRD.Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice. Behav Brain Res2018;
337:61–9
57.
LiuMYYinCYZhuLJZhuXHXuCLuoCXChenHZhuDYZhouQG.Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc2018;
13:1686–98
58.
OlneyJJMarshallSAThieleTE.Assessment of depression-like behavior and anhedonia after repeated cycles of binge-like ethanol drinking in male C57BL/6J mice. Pharmacol Biochem Behav2018;
168:1–7
59.
CaspiAHarringtonHMoffittTEMilneBJPoultonR.Socially isolated children 20 years later: risk of cardiovascular disease. Arch Pediatr Adolesc Med2006;
160:805–11
60.
UherRPerroudNNgMYHauserJHenigsbergNMaierWMorsOPlacentinoARietschelMSoueryDZagarTCzerskiPMJermanBLarsenERSchulzeTGZobelACohen-WoodsSPirloKButlerAWMugliaPBarnesMRLathropMFarmerABreenGAitchisonKJCraigILewisCMMcGuffinP.Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry2010;
167:555–64
61.
MénardCPfauMLHodesGERussoSJ.Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology2017;
42:62–80
62.
LuQMouriAYangYKunisawaKTeshigawaraTHirakawaMMoriYYamamotoYLiboZNabeshimaTSaitoK.Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression. Behav Brain Res2019;
372:112053
63.
YangCRZhangZGBaiYYZhouHFZhouLRuanCSLiFLiCQZhengHYShenLJZhouXF.Foraging activity is reduced in a mouse model of depression. Neurotox Res2014;
25:235–47
ChaudhuryDWalshJJFriedmanAKJuarezBKuSMKooJWFergusonDTsaiHCPomeranzLChristoffelDJNectowAREkstrandMDomingosAMazei-RobisonMSMouzonELoboMKNeveRLFriedmanJMRussoSJDeisserothKNestlerEJHanMH.Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature2013;
493:532–6
66.
HeshmatiMAleyasinHMenardCChristoffelDJFlaniganMEPfauMLHodesGELepackAEBicksLKTakahashiAChandraRTureckiGLoboMKMazeIGoldenSARussoSJ.Cell-type-specific role for nucleus accumbens neuroligin-2 in depression and stress susceptibility. Proc Natl Acad Sci U S A2018;
115:1111–6
67.
BergaminiGMechtersheimerJAzzinnariDSigristHBuergeMDallmannRFreijeRKourakiAOpacka-JuffryJSeifritzEFergerBSuterTPryceCR.Chronic social stress induces peripheral and central immune activation, blunted mesolimbic dopamine function, and reduced reward-directed behaviour in mice. Neurobiol Stress2018;
8:42–56
68.
ShimamotoA.Social defeat stress, sex, and addiction-Like behaviors. Int Rev Neurobiol2018;
140:271–313
69.
BursteinODoronR.The unpredictable chronic mild stress protocol for inducing anhedonia in mice. J Vis Exp 2018;
140:58184.
70.
HendrieCAPicklesAR.Depression as an evolutionary adaptation: implications for the development of preclinical models. Med Hypotheses2009;
72:342–7
71.
TyeKMMirzabekovJJWardenMRFerencziEATsaiHCFinkelsteinJKimSYAdhikariAThompsonKRAndalmanASGunaydinLAWittenIBDeisserothK.Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature2013;
493:537–41
72.
FreundNThompsonBSSonntagKMedaSAndersenSL.When the party is over: depressive-like states in rats following termination of cortical D1 receptor overexpression. Psychopharmacology2016;
233:1191–201
73.
BagotRCPariseEMPeñaCJZhangHXMazeIChaudhuryDPersaudBCachopeRBolaños-GuzmánCACheerJFDeisserothKHanMHNestlerEJ.Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nat Commun2015;
6:7062
74.
de JongJWAfjeiSAPollak DorocicIPeckJRLiuCKimCKTianLDeisserothKLammelS.A neural circuit mechanism for encoding aversive stimuli in the mesolimbic dopamine system. Neuron2019;
101:133–51 e7
75.
WardenMRSelimbeyogluAMirzabekovJJLoMThompsonKRKimSYAdhikariATyeKMFrankLMDeisserothK.A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature2012;
492:428–32
76.
SidorMMSpencerSMDzirasaKParekhPKTyeKMWardenMRAreyRNEnwrightJF 3rdJacobsenJPKumarSRemillardEMCaronMGDeisserothKMcClungCA.Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol Psychiatry2015;
20:1406–19
MatthewsGANiehEHVander WeeleCMHalbertSAPradhanRVYosafatASGloberGFIzadmehrEMThomasRELacyGDWildesCPUnglessMATyeKM.Dorsal raphe dopamine neurons represent the experience of social isolation. Cell2016;
164:617–31
ShinoharaRTaniguchiMEhrlichATYokogawaKDeguchiYCherasseYLazarusMUradeYOgawaAKitaokaSSawaANarumiyaSFuruyashikiT.Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice. Mol Psychiatry2018;
23:1717–30
PizzagalliDABerrettaSWootenDGoerFPilobelloKTKumarPMurrayLBeltzerMBoyer-BoiteauAAlpertNEl FakhriGMechawarNVitalianoGTureckiGNormandinM.Assessment of striatal dopamine transporter binding in individuals with major depressive disorder: in vivo positron emission tomography and postmortem evidence. JAMA Psychiatry2019;
76:854–61
83.
PizzagalliDAHolmesAJDillonDGGoetzELBirkJLBogdanRDoughertyDDIosifescuDVRauchSLFavaM.Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry2009;
166:702–10
84.
ForbesEEHaririARMartinSLSilkJSMoylesDLFisherPMBrownSMRyanNDBirmaherBAxelsonDADahlRE.Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry2009;
166:64–73
85.
KuniiYZhangWXuQHydeTMMcFaddenWShinJHDeep-SoboslayAYeTLiCKleinmanJEWangKHLipskaBK.CHRNA7 and CHRFAM7A mRNAs: co-localized and their expression levels altered in the postmortem dorsolateral prefrontal cortex in major psychiatric disorders. Am J Psychiatry2015;
172:1122–30
86.
CathomasFMurroughJWNestlerEJHanMHRussoSJ.Neurobiology of resilience: interface between mind and body. Biol Psychiatry2019;
86:410–20
87.
AnsorgeMSHenRGingrichJA.Neurodevelopmental origins of depressive disorders. Curr Opin Pharmacol2007;
7:8–17
88.
SuriDTeixeiraCMCagliostroMKMahadeviaDAnsorgeMS.Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors. Neuropsychopharmacology2015;
40:88–112
89.
CourtinJChaudunFRozeskeRRKaralisNGonzalez-CampoCWurtzHAbdiABaufretonJBienvenuTCHerryC.Prefrontal parvalbumin interneurons shape neuronal activity to drive fear expression. Nature2014;
505:92–6
90.
GrahamDLDuraiHHGardenJDCohenELEchevarriaFDStanwoodGD.Loss of dopamine D2 receptors increases parvalbumin-positive interneurons in the anterior cingulate cortex. ACS Chem Neurosci2015;
6:297–305
91.
NorthoffGSibilleE.Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol Psychiatry2014;
19:966–77
92.
SauerJFStruberMBartosM.Impaired fast-spiking interneuron function in a genetic mouse model of depression. eLife 2015;
4:e04979.
93.
SibilleEMorrisHMKotaRSLewisDA.GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol2011;
14:721–34
94.
FlamesNMarinO.Developmental mechanisms underlying the generation of cortical interneuron diversity. Neuron2005;
46:377–81
95.
JonesEG.The origins of cortical interneurons: mouse versus monkey and human. Cereb Cortex2009;
19:1953–6
XuQCobosIDe La CruzERubensteinJLAndersonSA.Origins of cortical interneuron subtypes. J Neurosci2004;
24:2612–22
98.
GasparPBlochBLe MoineC.D1 and D2 receptor gene expression in the rat frontal cortex: cellular localization in different classes of efferent neurons. Eur J Neurosci1995;
7:1050–63
99.
MulyEC 3rdSzigetiKGoldman-RakicPS.D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. J Neurosci1998;
18:10553–65
100.
ThompsonBLStanwoodGDLevittP.Specificity of prenatal cocaine exposure effects on cortical interneurons is independent from dopamine D1 receptor co-localization. J Chem Neuroanat2010;
39:228–34
101.
XuLZhangXH.Distribution of D1 and D2-dopamine receptors in calcium-binding-protein expressing interneurons in rat anterior cingulate cortex.Sheng Li Xue Bao2015;
67:163–72.
102.
MoneyKMStanwoodGD.Developmental origins of brain disorders: roles for dopamine. Front Cell Neurosci2013;
7:260
103.
FrederickALStanwoodGD.Drugs, biogenic amine targets and the developing brain. Dev Neurosci2009;
31:7–22
104.
ThompsonBLLevittPStanwoodGD.Prenatal exposure to drugs: effects on brain development and implications for policy and education. Nat Rev Neurosci2009;
10:303–12
105.
FrancisTCGaynorAChandraRFoxMELoboMK.The selective RhoA inhibitor rhosin promotes stress resiliency through enhancing D1-medium spiny neuron plasticity and reducing hyperexcitability. Biol Psychiatry2019;
85:1001–10
106.
JonesLBStanwoodGDReinosoBSWashingtonRAWangHYFriedmanELevittP.In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J Neurosci2000;
20:4606–14
107.
SongZMUndieASKohPOFangYYZhangLDrachevaSSealfonSCLidowMS.D1 dopamine receptor regulation of microtubule-associated protein-2 phosphorylation in developing cerebral cortical neurons. J Neurosci2002;
22:6092–105
108.
StanwoodGDParlamanJPLevittP.Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D1 receptor mutant mice. J Comp Neurol2005;
487:270–82
109.
StanwoodGDParlamanJPLevittP.Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G-protein signalling (Rgs) transcripts. Eur J Neurosci2006;
24:806–18
110.
StanwoodGDWashingtonRALevittP.Identification of a sensitive period of prenatal cocaine exposure that alters the development of the anterior cingulate cortex. Cereb Cortex2001;
11:430–40
111.
CrandallJEMcCarthyDMArakiKYSimsJRRenJQBhidePG.Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J Neurosci2007;
27:3813–22
112.
OhtaniNGotoTWaeberCBhidePG.Dopamine modulates cell cycle in the lateral ganglionic eminence. J Neurosci2003;
23:2840–50
113.
BrownRWFlaniganTJThompsonKNThackerSKSchaeferTLWilliamsMT.Neonatal quinpirole treatment impairs Morris water task performance in early postweanling rats: relationship to increases in corticosterone and decreases in neurotrophic factors. Biol Psychiatry2004;
56:161–8
114.
PruessnerJCChampagneFMeaneyMJDagherA.Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci2004;
24:2825–31
115.
PruessnerJCDedovicKPruessnerMLordCBussCCollinsLDagherALupienSJ.Stress regulation in the central nervous system: evidence from structural and functional neuroimaging studies in human populations – 2008 Curt Richter Award Winner. Psychoneuroendocrinology2010;
35:179–91
116.
TeicherMHAndersenSLPolcariAAndersonCMNavaltaCPKimDM.The neurobiological consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev2003;
27:33–44
117.
BurkeARMiczekKA.Stress in adolescence and drugs of abuse in rodent models: role of dopamine, CRF, and HPA axis. Psychopharmacology2014;
231:1557–80
118.
ErnstMRomeoRDAndersenSL.Neurobiology of the development of motivated behaviors in adolescence: a window into a neural systems model. Pharmacol Biochem Behav2009;
93:199–211
119.
PausTKeshavanMGieddJN.Why do many psychiatric disorders emerge during adolescence?Nat Rev Neurosci2008;
9:947–57
